Following a year of significant pharma acquisitions, approvals of transformative drugs the first of their kind, and a surge of financial backing to bolster innovation in new targets and preclinical pipelines, 2025 is set to continue this momentum, with more companies prioritizing neuroscience drug development than ever before, thanks to:

• Huge breakthroughs in neuroscience discovery with state-of-the-art screening technologies
• In vitro preclinical model advances, including 3D brain organoids and IPSC-derived microglia
• Implementation of novel blood-based and digital biomarkers for non-invasive and objective measurements
• Next-generation rodent, pig, and NHP models with enhanced human relevance and translatability
• Brand new drug delivery innovations to overcome the blood-brain barrier and unlock deeper brain regions
• Clinical innovations to navigate heterogeneous patient populations, streamline recruitment, and navigate regulatory challenges